Changes of Serum C-Reactive Protein Level in Patients With Depressive Disorders After Treatment With Agomelatine Combined With Aerobic Exercise and Its Significance
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Changes of Serum C-Reactive Protein Level in Patients With Depressive Disorders After Treatment With Agomelatine Combined With Aerobic Exercise and Its Significance
Authors
Keywords
-
Journal
CLINICAL NEUROPHARMACOLOGY
Volume 46, Issue 5, Pages 192-197
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-09-12
DOI
10.1097/wnf.0000000000000568
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- C-Reactive Protein as a Biomarker for Major Depressive Disorder?
- (2022) Laura Orsolini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of aerobic exercise on quality of life of people with HIV-associated neurocognitive disorder on antiretroviral therapy: a randomised controlled trial
- (2022) Martins Nweke et al. BMC INFECTIOUS DISEASES
- Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway
- (2022) Tian Lan et al. Journal of Neuroinflammation
- What's Race Got to Do With It? CRP Levels in Immune Mediated Skin Diseases: Considerations for Hidradenitis Suppurativa
- (2022) Chidubem A. V. Okeke et al. Frontiers in Immunology
- Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
- (2022) Eugenia Papalexi et al. BMC Psychiatry
- Correlation Between Serum High-Sensitivity C-Reactive Protein, Tumor Necrosis Factor-Alpha, Serum Interleukin-6 and White Matter Integrity Before and After the Treatment of Drug-Naïve Patients With Major Depressive Disorder
- (2022) Liping Chen et al. Frontiers in Neuroscience
- Suppressors of Cytokine Signaling Are Decreased in Major Depressive Disorder Patients
- (2022) Nobuyuki Kobayashi et al. Journal of Personalized Medicine
- Animal models for the study of depressive disorder
- (2021) Juhyun Song et al. CNS Neuroscience & Therapeutics
- Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone: A systematic review and meta-analysis of randomized controlled trials
- (2021) Jacqueline Lee et al. JOURNAL OF AFFECTIVE DISORDERS
- Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
- (2021) Shek Ming Leung Brain and Behavior
- Agomelatine: An astounding sui-generis antidepressant?
- (2021) Muhammad Naveed et al. Current Molecular Pharmacology
- Precision non-implantable neuromodulation therapies: a perspective for the depressed brain
- (2020) Lucas Borrione et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- The preclinical discovery and development of agomelatine for the treatment of depression
- (2020) George Konstantakopoulos et al. Expert Opinion on Drug Discovery
- A randomized trial of aerobic exercise for major depression: examining neural indicators of reward and cognitive control as predictors and treatment targets
- (2020) C. J. Brush et al. PSYCHOLOGICAL MEDICINE
- Decreased integration of the frontoparietal network during a working memory task in major depressive disorder
- (2020) Wenjian Tan et al. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
- Effectiveness of physical exercise in the treatment of depression in older adults as an alternative to antidepressant drugs in primary care
- (2019) Jesús López-Torres Hidalgo et al. BMC Psychiatry
- The acute effects of aerobic exercise on sleep in patients with depression: study protocol for a randomized controlled trial
- (2019) Gavin Brupbacher et al. Trials
- Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales
- (2018) Elizabeth D. Ballard et al. JOURNAL OF AFFECTIVE DISORDERS
- Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light
- (2018) Jana Tchekalarova et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Sprint interval training (SIT) substantially reduces depressive symptoms in major depressive disorder (MDD): A randomized controlled trial
- (2018) Alice Minghetti et al. PSYCHIATRY RESEARCH
- Exercise effects on depression: Possible neural mechanisms
- (2017) Swathi Gujral et al. GENERAL HOSPITAL PSYCHIATRY
- Agomelatine, venlafaxine, and running exercise effectively prevent anxiety- and depression-like behaviors and memory impairment in restraint stressed rats
- (2017) Sarawut Lapmanee et al. PLoS One
- Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
- (2016) Domenico De Berardis et al. CNS SPECTRUMS
- Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
- (2015) Domenico De Berardis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lifestyle medicine for depression
- (2014) Jerome Sarris et al. BMC Psychiatry
- MAJOR DEPRESSIVE DISORDER IN DSM-5: IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH OF CHANGES FROM DSM-IV
- (2013) Rudolf Uher et al. DEPRESSION AND ANXIETY
- Effect of running therapy on depression (EFFORT-D). Design of a randomised controlled trial in adult patients [ISRCTN 1894]
- (2012) Frank R Kruisdijk et al. BMC PUBLIC HEALTH
- Cardiovascular Abnormalities in Patients with Major Depressive Disorder
- (2009) Alex D.H. Brown et al. CNS DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search